Hormone Receptor Positive Breast Cancer

ASCO Breast Cancer

ASCO GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/71360

Contents of this Issue

Navigation

Page 7 of 7

Abbreviations AE, adverse event; AI, aromatase inhibitor; CVD, cardiovascular disease; CYP2D6, Cytochrome P450 2D6; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor; VTE, venous thromboembolism Source Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ. American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer. J Clin Oncol. August 10, 2010, vol. 28, no. 23: 3784-3796. Disclaimer This resource is a practice tool for physicians based on an ASCO® guideline and this tool are not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients and may not reflect the most recent evidence. This tool does not recommend any particular product or course of medical treatment. Use of the practice guideline and this resource is voluntary. The full practice guideline and additional information are available at http://www.asco.org/guidelines. Copyright © 2010 by American Society of Clinical Oncology® practice guideline. The practice . All rights reserved. 5740 Executive Drive Suite 220 Baltimore, MD 21228 TEL: 410-869-3332 • FAX: 410-744-2150 For additional copies: orders@GuidelineCentral.com Copyright © 2010 All rights reserved

Articles in this issue

Links on this page

Archives of this issue

view archives of Hormone Receptor Positive Breast Cancer - ASCO Breast Cancer